-
Immunicum is advancing a novel immuno-oncology approach to treat solid tumors through its lead program ilixadencel
Immunicum is listed on NASDAQ Stockholm under the ticker IMMU
Tweets by @Immunicum
Tweets by ImmunicumNews
-
Transaction Webcast Presentation
19 Nov 2020 -
Transaction Webcast Details
18 Nov 2020 -
Allogeneic inflammatory dendritic cells, Mimicking anti-viral innate immunity against cancer
13 Oct 2020 -
ESMO Virtual Congress 2020 Poster Presentation
17 Sep 2020 -
Get to know Dr Sven Rohmann our new CEO
15 Sep 2020
About us
Developing innovative cancer immunotherapies
Immunicum is advancing a novel cell-based approach to target solid tumors.
Learn more
